investors
sec-filings

Event Details

Denali Therapeutics to Present Data from Phase 1 Clinical Study for LRRK2 Inhibitor Program in Healthy Volunteers at the 12th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference